Schroder Investment Management Group
CTMX icon

Schroder Investment Management Group’s CytomX Therapeutics CTMX Stock Holding History

Schroder Investment Management Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,366
Closed -$44K – 1235
2018
Q3 		$44K Buy
+2,366
New +$53.9K ﹤0.01% 1211
2018
Q2 		– Sell
-42,546
Closed -$1.21M – 1279
2018
Q1 		$1.21M Sell
42,546
-36,891
-46% -$1.05M ﹤0.01% 911
2017
Q4 		$1.68M Buy
79,437
+52,348
+193% +$1.09M ﹤0.01% 921
2017
Q3 		$489K Buy
+27,089
New +$423K ﹤0.01% 1078

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Schroder Investment Management Group's CTMX Position: Q4 2018 in Review

Schroder Investment Management Group sold out of CytomX Therapeutics (CTMX) in Q4 2018, closing a stake of 2,366 shares — an estimated $44K sold.

Schroder Investment Management Group first reported a position in CTMX in Q3 2017 and held it in 4 quarters. The position peaked at $1.68M in Q4 2017. 111 funds tracked by Wall St. Rank hold CTMX as of Q4 2018.

  • Schroder Investment Management Group reported no remaining CytomX Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Schroder Investment Management Group sold 2,366 CytomX Therapeutics shares in Q4 2018, an estimated $44K.
  • Schroder Investment Management Group first reported a position in CytomX Therapeutics in Q3 2017 and held it in 4 quarters.
  • Schroder Investment Management Group's CytomX Therapeutics position peaked at $1.68M in Q4 2017.
  • 111 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2018.

Based on Schroder Investment Management Group's 13F filing for Q4 2018, filed 14 Feb 2019.